𝗗𝗮𝗶𝗶𝗰𝗵𝗶 𝗦𝗮𝗻𝗸𝘆𝗼 𝗯𝗿𝗶𝗻𝗴𝘀 𝗚𝗹𝘆𝗰𝗼𝘁𝗼𝗽𝗲 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗶𝗻-𝗵𝗼𝘂𝘀𝗲 𝗳𝗼𝗿 ...
Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...
The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...
(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...
An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback